Highly potent TACC3 inhibitor as a novel anticancer drug candidate
US11622966B2 · kind B2 · utility
1Cited by
1References
18Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Mar 14, 2019 |
| Grant date | Apr 11, 2023 |
| Priority date | — |
| Expiry date | Sep 18, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a new inhibitor chemotype 3-(4-methoxyphenyl)-N-(2-morpholinopyrimidin-4-yl) isoxazol-5-amine (BO-264) targeting TACC3 protein with high potency as a mitotic blocker for the treatment of breast and potentially other cancers.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.